


## ZDLD20

<b>Cat. No.:</b>	HY-115909		
<b>CAS No.:</b>	2762279-02-5		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>22</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	386.45		
<b>Target:</b>	CDK		
<b>Pathway:</b>	Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (64.69 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5877 mL	12.9383 mL	25.8766 mL
5 mM	0.5175 mL	2.5877 mL	5.1753 mL
10 mM	0.2588 mL	1.2938 mL	2.5877 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

ZDLD20, a  $\beta$ -carboline, is orally active and selective CDK4/CycD3 inhibitor with an IC<sub>50</sub> value of 6.51  $\mu$ M. ZDLD20 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD20 exhibits potent anticancer activity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

CDK4/CycD3  
6.51  $\mu$ M (IC<sub>50</sub>)

### REFERENCES

[1]. Deping Li, et al. Facile synthesis of C1-substituted  $\beta$ -carbolines as CDK4 inhibitors for the treatment of cancer. *Bioorg Chem.* 2022 Apr;121:105659.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA